Phase 1/2RecruitingAge-related condition
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
A First in Human Phase 1 / 2 Multi-center Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of CTx001 Administered Via a Single Subretinal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- Sponsor
- Complement Therapeutics (Industry)
- Enrolment
- 75 planned
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- CTx001
- Ages
- adults, older adults
- Registry
- NCT07392255
Full record on ClinicalTrials.gov
From the registry
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.
Primary outcomes
- To monitor the safety and tolerability of a single administration of CTx001 at 3 dose levels
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started